Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome.

Authors:
Goodoory VC; Ng CE; Black CJ; Ford AC.

Journal:
Aliment Pharmacol Ther

Publication Year: 2022

DOI:
10.1111/apt.16816

PMCID:
PMC9303338

PMID:
35166374

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Aliment Pharmacol Ther

Abbreviation: Aliment Pharmacol Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic…
Wijarnpreecha K; Li F; Lundin SK and 5 more (2023) - Transparency Score: 3/6
Longer time to recovery from acute kidney injury is associated with major adverse kidney events in …
Patidar KR; Naved MA; Kabir S and 9 more (2023) - Transparency Score: 3/6
A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for s…
Hermann RP; Rockey DC; Suzuki A and 2 more (2022) - Transparency Score: 3/6
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disea…
Meade S; Patel KV; Luber RP and 17 more (2022) - Transparency Score: 4/6
Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogas…
Visaggi P; Ghisa M; Del Corso G and 11 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of personal interest : None. Declaration of funding interest : Unrestricted research monies were provided by Tillotts Pharma UK Ltd ‐ grant number RG.GASS.124592. The funder had no input into the concept, design, analysis, or reporting of the study."

Evidence found in paper:

"Declaration of funding interest: Unrestricted research monies were provided by Tillotts Pharma UK Ltd ‐ grant number RG.GASS.124592. The funder had no input into the concept, design, analysis, or reporting of the study."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025